Dose-dense weekly chemotherapy in advanced ovarian cancer: An updated meta-analysis of randomized controlled trials

Ovarian cancer (OC) represents, for incidence, the sixth most common cancer worldwide, and it is characterized by poor prognosis (Torre et al., 2016). Intravenous 3-weekly carboplatin and paclitaxel remain the standard chemotherapy drugs for first-line therapy in advanced OC, after complete cytoreductive surgery is achieved (Anon., 2017a). Over the ears, modifications in adjuvant chemotherapy regimen, including dose-dense schedules, have been investigated in different trials and provided conflicting results regarding clinical outcomes and toxicity.

Source: Critical Reviews in Oncology Hematology - March 7, 2018 Category: Cancer & Oncology Authors: C. Marchetti, F. De Felice, A. Di Pinto, O. D ’Oria, N. Aleksa, A. Musella, I. Palaia, L. Muzii, V. Tombolini, P. Benedetti Panici Source Type: research